Patient and treatment characteristics
| Patient characteristic | |
| Age (years), median (range) | 34 (26–60) |
| Histology, n (%) | |
| Squamous cell carcionoma | 10 (53) |
| Adenocarcinoma | 5 (26) |
| Adenosquamous carcinoma | 4 (21) |
| Stage (FIGO 2018), n (%) | |
| IA1 | 2 (11) |
| IA2 | 1 (5) |
| IB1 | 7 (37) |
| IB2 | 8 (42) |
| IB3 | 1 (5) |
| Volume disease, n (%) | |
| Micrometastasis | 10 (53) |
| Isolated tumor cells | 9 (47) |
| Surgical treatment, n (%) | |
| Cone biopsy | 2 (11) |
| Radical trachelectomy | 4 (20) |
| Simple hysterectomy | 2 (11) |
| Radical hysterectomy | 11 (58) |
| Pelvic lymphadenectomy, n (%) | |
| No | 12 (63) |
| Unilateral | 3 (16) |
| Bilateral | 4 (21) |
| Para-aortic lymphadenectomy, n (%) | |
| No | 15 (79) |
| Yes | 4 (21) |
| Cervical tumor size (mm), median (range) | 18 (1–44) |
| Depth of stromal invasion (mm), median (range) | 8.8 (0.8–20) |
| Adjuvant treatment, n (%) | |
| No | 5 (26) |
| Radiation therapy only | 1 (5) |
| Chemotherapy only | 3 (16) |
| Radiation and chemotherapy | 10 (53) |
| Intermediate-risk (Sedlis) criteria, n (%) | |
| No | 11 (58) |
| Yes | 8 (42) |
| Follow-up (months), median (range) | 62 (13–94) |
FIGO, International Federation of Gynecology and Obstetrics.